GLP-1 Agonist

Lupin Expands Diabetes Portfolio with Gan & Lee’s Fortnightly GLP-1 Agonist

• Created December 30, 2025
• Author saurav chaube
• Reading Time: 2 minutes

Lupin has taken a significant strategic step to strengthen its presence in the fast-growing diabetes and obesity treatment space by entering into an exclusive license, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals. The partnership brings Bofanglutide, a novel f...